Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Rational design of plant systems for sustainable generation of value-added industrial products (SMARTCELL)

Framework: FP7 — Cooperation
Programme: Food, Agriculture and Fisheries, and Biotechnology
Destination: Life sciences, biotechnology and biochemistry for sustainable non-food products and processes
Action type: Collaborative project
Countries involved: Finland,Belgium,Netherlands,Spain,Germany,Switzerland,Belgium,France,United Kingdom,Denmark,United Kingdom,Netherlands,France,France,United States
Call:  (FP7-KBBE-2007-2A, 2007)
Start date: 2009-01-01
End date: 2013-09-30
Duration (months): 57.0
Total project cost (EUR): 8061603.2
EU funding (EUR): 5901866.0
Participants: 19
Project status: CLOSED

Plants sustainably produce low levels of secondary metabolites of high industrial value. However, they are often too complex to be economically manufactured by chemical synthesis. Advanced metabolic engineering and exploitation of plants as Green Factories has been prevented due to poorly understood metabolic pathways in plants and the regulation thereof. SmartCell brings together 14 leading European academic laboratories and four industrial partners in order to create a novel concept for rationally engineering plants towards improved economical production of high-value compounds for non-food industrial use. Although SmartCell focuses on terpenoids, the largest class of secondary metabolites, which exhibit extremely diverse biological and pharmaceutical activities, all knowledge, tools and resources developed in the project, are generic and broadly applicable to engineer any plant biosynthetic pathway. A systems biology approach using metabolomics and transcriptomics is taken to move beyond the state of the art. New multigene transfer technologies are developed. By screening and functionally categorizing genes at structural, regulatory and transport levels a comprehensive knowledge base of how secondary metabolite biosynthetic pathways operate in plants is developed. The case study component i.e. manufacturing a valuable terpenoid in an optimized large-scale system gives SmartCell a unique opportunity to directly make transition from fundamental science to application. For long-term exploitation an integrated database, compound library, cell culture collection and a genebank available for academic and industrial communities will be established. SmartCell provides new opportunities for SMEs and established European biotech companies, and the technology can also be transferred to other e.g. fine chemical and pharmaceutical industries. SmartCell will prove that plant-based resources can furnish the European society and industry far more than they presently do.

Keywords: secondary metabolites,terpenoids,genetic engineering,metabolomics,transcriptomics,large-scale production,manufacturing,plant,plant cells
FEAST Extension, Enhancement and Demonstration project (FEED)

Framework: FP7 — Capacities
Programme: Activities of International Cooperation
Destination: Bilateral coordination for the enhancement and development of S&T Partnerships
Action type: Coordination and support actions
Countries involved: Australia
Call:  (FP7-INCO-2007-2, 2007)
Start date: 2008-05-01
End date: 2012-06-30
Duration (months): 50.0
Total project cost (EUR): 1016412.0
EU funding (EUR): 456300.0
Participants: 1
Project status: CLOSED

This project seeks to maximise the likelihood that opportunities for attractive and feasible research cooperation exploiting Australian capability of benefit to Europe are used effectively. It also seeks to maximise the likelihood that Australian researchers can exploit attractive and feasible cooperation opportunities with the far larger European research, development and demonstration effort. This will be achieved by: (a) clarifying and widely communicating information on competitive Australian research, development and demonstration capabilities in key thematic areas via a Thematic Collaboration Roadmaps work package; (b) identifying and widely communicating best practice strategies and tactics that enable Australian and European researchers to engage effectively via a Best Practice Strategies and Tactics work package; (c) liaising with Member States, other European nations, the European funded Europe Centres in Australia and other FEAST-type units in other nations in order to exchange information and experiences on maximising the effectiveness of this type of facilitation via a Liaison work package; (d) clearly and verifiably demonstrating the additionality of this research cooperation facilitation function via developing an Impact Monitoring System. Via these actions the project will address expected outcomes in the activities of international cooperation within FP7 by: improving the process of providing information on programs and funding designed to promote cooperation between Europe and Australia; better identifying and demonstrating mutual interest and benefit in S&T cooperation between the EU and Australia, and; sharing best practices via joint workshops and presenting the best prospects for cooperation in particular fields. In so doing, the project will extend and enhance the capability of the established activities of the Forum for European-Australian Science and Technology cooperation (FEAST).

Keywords: australia,international collaboration,third country,network,feast,innovation,member states,r&d,research development and demonstration
High-Density Peptide MicroArrays and Parallel On-line Detection of Peptide-Ligand Interactions (PEPCHIPOMICS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Denmark,France,European organisations area,Denmark,Sweden,Germany,Denmark
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2008-10-01
End date: 2012-03-31
Duration (months): 42.0
Total project cost (EUR): 3837556.8
EU funding (EUR): 2939065.0
Participants: 7
Project status: CLOSED

Proteins are crucial structural and functional elements of life, and frequent targets of intervention. Short protein sequences, conventionally defined as peptides, have emerged as indispensable tools in biotechnology: peptides may represent short linear protein structures, and in some cases they even mimic more complex discontinuous structures. Custom-made synthetic peptides cost down to ca. 30 EURO (decamer, few mg, moderate purity); yet, a comprehensive screening program can easily cost 100,000'es of EUROs, and the cost of the screening program may itself be prohibitive due to the logistics of assaying many individual peptides. Thus, the pharmaceutical and biotechnology industries, as well as academia, encounter significant economic and logistical barriers, when they attempt to apply peptide-based screening programmes in the exploitation of "-omics" information. In the current proposal, we will use novel photochemistry to synthesise large arrays of peptides on chips the size of a stamp (from a few thousand up to more than a hundred thousand defined peptides) reducing the cost of synthesis to a few cents per peptide. To detect analyte interactions with individual peptide moieties, we use both label-dependent optical detection (10e4 to 10e5 different peptides per chip), as well as label-independent recording of binding kinetics measuring rates and strengths of interactions simultaneously for up to 2000 peptides. Bioinformatics will be used to interpret microarray data, and guide the design of subsequent iterative peptide microarrays thereby greatly enhancing the number of peptide specificities that otherwise can be handled at the level of a single peptide chip. This will allow acquisition of peptide and protein data at an unprecedented scale and quality, at a fraction of the cost and time associated with other current technologies. For the SME's, this project will support their innovation and validation, and provide significant new market possibilities.

Keywords: proteomics,peptide microarray,surface plasmon resonance,bioinformatics
Bilateral Support for the International Linkage with Kina (BILAT SILK)

Framework: FP7 — Capacities
Programme: Activities of International Cooperation
Destination: Bilateral coordination for the enhancement and development of S&T Partnerships
Action type: Coordination and support actions
Countries involved: Sweden,Italy,Greece,United Kingdom,China
Call:  (FP7-INCO-2007-2, 2007)
Start date: 2008-12-01
End date: 2011-11-30
Duration (months): 36.0
Total project cost (EUR): 612583.0
EU funding (EUR): 496379.74
Participants: 5
Project status: CLOSED

BILAT SILK will raise the EU’s science and technology profile in China by a series of promotional activities to disseminate the EU’s research policies and actions among Chinese scientists and research institutions. Strategic partnerships between 4 EU countries and China will be promoted through collaboration schemes and identification of new activities. BILAT SILK will identify and demonstrate mutual interest and benefit in the cooperation between the EU and China sharing best practises via workshops and presenting the state of the art and the prospects for cooperation in particular fields. BILAT SILK will also identify 6 research areas of interest between the EU and China, with the ultimate aim of better strengthening and benefit from science and technology cooperation. The activities foreseen aim at elaborating a detailed mapping of joint research themes between EU and China and enhancing the cooperation. Furthermore BILAT SILK will analyze the state-of-the-art of methodologies and practices used in current European and Chinese Technology Assessment (TA) as science and technology policy advisory, to identify common themes and practices and provide a comprehensive list of TA organisations For achieving an optimum participation of Chinese teams in the 7th FP BILAT SILK will provide efficient training of National and Regional Information Points through specialised trainings in specific FP7 issues but also special trainings in providing NCP services. Furthermore, the website of the Chinese NCP-organisation will be further enhanced and developed in order to provide info in the Chinese organisations and also a pool of partner profiles both Chinese and EU searchable by EU project coordinators.

Keywords: bilateral eu china cooperation,training,best practice,policy advisory
Evaluation of Integrated Cardiac Imaging for the Detection and Characterization of Ischemic Heart Disease (EVINCI-STUDY)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Italy,Finland,Switzerland,Netherlands,Germany,Spain,Poland,United Kingdom,France,Italy,Spain,Italy,France,Germany
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-01-01
End date: 2012-06-30
Duration (months): 42.0
Total project cost (EUR): 3432418.46
EU funding (EUR): 2695402.0
Participants: 22
Project status: CLOSED

The main purpose of the EVINCI-study is to test the impact of combined “anatomo-functional” non invasive cardiac imaging for detection and characterization of Ischemic Heart Disease (IHD). The EVINCI-study is a prospective clinical European multicenter trial performed in a cohort of 700 patients with suspected IHD. Patients with intermediate pre-test probability will undergo clinical and biohumoral characterization, including novel circulating markers of cardiovascular risk. They will be admitted to a non-invasive cardiac evaluation, consisting of “anatomic” imaging, by multislice computerized tomography, combined with “functional” tests among radionuclide, magnetic resonance and ultrasound imaging. Heart catheterization will be performed to validate non-invasive diagnosis and follow-up to assess outcome. The diagnostic accuracy of combined non-invasive “anatomo-functional” imaging will be tested against reference methods for diagnosing epicardial coronary lesions (coronary angiography), vessel wall atherosclerosis (intracoronary ultrasound) and impaired coronary flow reserve (intracoronary doppler/pressure wire). The individual profiles from “anatomo-functional” cardiac imaging and “clinical-biohumoral” data will be combined and tested against outcome. A cost-benefit analysis (including an estimate of procedural/radiological risks) of the new diagnostic work-up will also be performed. A relevant part of the EVINCI-study will be dedicated to the development, in cooperation with the industry, of an advanced informatics’ platform able to synthetically present to the end-user (patients, physicians, etc.) the integrated cardiological diagnostic profile of the individual patient as resulting from clinical-biohumoral and multi-imaging assessment. Overall results will be disseminated in cooperation with the European Society of Cardiology (ESC) and will guide the work of a dedicated ESC Commission which will release specific European Recommendations.

Keywords: coronary heart disease,imaging,scintigraphy,positron emission tomography,magnetic resonance imaging,echocardiography
Standardisation and improvement of generic pre-analytical tools and procedures for in vitro diagnostics (SPIDIA)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Germany,Austria,Italy,Sweden,France,Czechia,Belgium,France,Netherlands,Germany,Switzerland,Norway,Denmark,Denmark
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2008-10-01
End date: 2013-03-31
Duration (months): 54.0
Total project cost (EUR): 13823601.0
EU funding (EUR): 8981796.0
Participants: 17
Project status: CLOSED

In vitro diagnostics have allowed a great deal of progress in medicine but are limited by two factors: (a) the lack of guidelines in collection, handling, stabilisation and storage of biosamples which limits the reproducibility of subsequent diagnoses, and (b) its scale is restrained to the cellular level. To address this first point, this IP, SPIDIA, built of clinicians, academics, tool and assay developers, aims to develop quality guidelines for molecular in vitro diagnostics and to standardize the pre-analytical workflow in related procedures. Regarding the second point, SPIDIA aims to develop modern pre-analytical tools for diagnostics improving the stabilisation, handling and study of free biomolecules within blood, plasma, serum, tissues and tumours. Recent discoveries have revealed that RNA, DNA or proteins, released from pathological sites, like tumour cells or Alzheimer’s disease (AD) brain lesions, into the blood or as a secondary blood based response to the disease can serve as biomarkers for early and reliable molecular diagnosis of such debilitating diseases. Further discoveries have shown that the cellular profiles of these molecules and structures in clinical samples can change during transport and storage thus making clinical assay results and pharmaceutical research unreliable or even impossible. It will therefore be a decisive prerequisite for future and current diagnostic assays to develop standards and new technologies, tools and devices that eliminate the human error in the pre-analytical steps of in vitro diagnostics. At this crucial moment in the development of molecular diagnostics, SPIDIA proposes an IP that reunites 7 private research companies (including 4 SMEs), 1 private research institute, 6 public research organisms, including universities, hospitals and biobanks, one management SME and an official European Standards Organisation. This strong consortium is balanced and empowered to maximise the impacts of in vitro diagnostics on human health.

Keywords: standards,pre-analytical phase,in-vitro-diagnostics,molecular diagnostics,diagnostic tools,biomarkers,biomedical research,blood sample,tumour sample,tissue sample,quality assurance
Distributed European Infrastructure for Supercomputing Applications 2 (DEISA2)

Framework: FP7 — Capacities
Programme: Research Infrastructures
Destination: Support to existing research infrastructures
Action type: Combination of CP & CSA
Countries involved: Germany,Spain,Italy,Finland,United Kingdom,Germany,France,Netherlands,United Kingdom,Germany
Call:  (FP7-INFRASTRUCTURES-2007-2, 2007)
Start date: 2008-05-01
End date: 2011-04-30
Duration (months): 36.0
Total project cost (EUR): 18654000.0
EU funding (EUR): 10237000.0
Participants: 11
Project status: CLOSED

DEISA2 continues to support and develop a distributed high performance computing infrastructure by consolidating the existing DEISA infrastructure and extending its collaborative environment for capability computing and data management. The resulting infrastructure is unmatched world-wide in its heterogeneity and complexity, enabling the operation of a powerful supercomputing Grid built on top of national services, facilitating Europe’s ability to undertake world-leading computational science research. DEISA has already proved its relevance for advancing computational sciences in leading scientific and industrial disciplines within Europe and has paved the way towards the deployment of a cooperative European HPC ecosystem. The existing infrastructure is based on the tight coupling of eleven leading national supercomputers, using dedicated network interconnections of GEANT2 and the NRENs. In DEISA2, activities and services relevant for Application Enabling, Operation, and Technologies are continued and enhanced, as these are indispensable for the effective support of world-leading computational sciences in the area of supercomputing. The service provisioning model is extended from one that supports a single project to one supporting Virtual European Communities. Collaborative activities will be carried out with new European and other world-leading initiatives. Of strategic importance is the cooperation with the PACE initiative which is preparing for the installation of a limited number of leadership-class tier-0 supercomputers in Europe. For a future persistent European HPC ecosystem, as suggested by ESFRI, which integrates national tier-1 centres and the new tier-0 centres, DEISA2 will deliver a turnkey operational solution. For this goal, DEISA2 targets the integration of further national computing centres as Associated Partners. DEISA2 will also contribute to interoperation of distributed infrastructures.

Keywords: einfrastructure,supercomputer grid,distributed high performance computing,cooerative extreme computing,grand challenge applications
Clinical Continuity by Integrated Care (HOMECARE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: Denmark,Netherlands,Italy,United Kingdom,Denmark,Denmark,Sweden,Portugal,Poland,Spain
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-04-01
End date: 2012-03-31
Duration (months): 36.0
Total project cost (EUR): 2750161.6
EU funding (EUR): 2159991.0
Participants: 13
Project status: CLOSED

Our comprehensive approach to clinical continuity by integrated care (IC) across the secondary-primary interface departs from a preliminary literature review selecting frequent chronic conditions (CC) as stroke, COPD and HF as our focus areas. However, within each of these areas IC is a small activity, still, requiring more basic research. As IC for these different CC are based on the same patient values (feeling safe, participation and primary feedback) the synergistic effect from cross-sectional relationships arising from this project should be significant. In all, our 11 deliverables may be important to trespass the critical mass required for an expansion of this kind of IC as far as justified by the empirical results. In general, moderately improved health at minimal costs might be expected from some point of their life to a large segment of the population in EU suffering from the CC in study. That would deliver goodwill to the EU! Special projects are going to investigate the relevance of the access to health improvements by these Low-Tech-IC-interventions in low- and middle-income MS with distinct problems of fragmented care systems. The project has several milestones: 1) A kick-off Symposium aiming to establish a common decision-making framework introducing the HTA method 2) A systematic literature review checking preliminary choices of focus areas after 6 months 3) After 18 months a comprehensive status of the progress of the different trials and surveys is scheduled with respect to both timeliness and scientific content 4) After 30 months the practical IC-guides for clinicians on stroke, heart failure and COPD, respectively, should be concluded after an extensive hearing in an international network related to the 2nd Annual meeting of the consortium. 5) After 36 months the final reporting and dissemination of an HTA of IC should provide the top level of clinical, administrative and political decision-makers with a solid base for progressive decision-making. In conclusion, a meso-strategy for dissemination of IC in EU with formation of a country-specific, multidisciplinary network of specialists in the involved fields as corner-stone for setting up new clinical implementations and recommendations for adaptation of financial and organisation conditions.

Keywords: clinical continuity esd home care rehabilitation stroke copd heart failure integrated care hta
A comprehensive dissection of pneumococcal-host interactions (PNEUMOPATH)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: United Kingdom,France,Netherlands,Sweden,Iceland,Italy,Germany,Portugal,Netherlands,France,France,United Kingdom
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-03-01
End date: 2012-08-31
Duration (months): 42.0
Total project cost (EUR): 4149765.0
EU funding (EUR): 2999839.0
Participants: 15
Project status: CLOSED

This project is a fundamental, comprehensive study of the host-pathogen interactions during infection with Streptococcus pneumoniae. The expectation is that the basic knowledge gained from this work will give new targets for vaccination, diagnosis and treatment. In PNEUMOPATH, academic and industrial partners will work together in six scientific workpackages. 1) The molecular epidemiology of antibiotic resistant pneumococci 2) The genetic basis of disease susceptibility in the human host and in mice 3) Molecular aspects of virulence and host response in animal models of pneumococcal carriage and disease 4) Molecular aspects of virulence and host response in human cell culture systems 5) Pneumococcal cell biology to determine the role of central metabolic processes and the link to virulence 6) Integrated bioinformatics and data management It is accepted that the outcome of pneumococcal infection is determined by the interplay of both host and pathogen attributes. Pneumococcal isolates vary in the repertoire of genes that they possess. Hence the contribution of an individual factor to the infectious process may vary according to the other host and pathogen factors that are present. To date, study of infection has tended to be a reductionist approach, considering the contribution of each virulence factor or host factor in isolation. Consequently, in searching for targets for antimicrobial therapy or for enhancement of host defence, the contribution of individual factors may be inaccurately estimated. This project will be radically different. Rather than using targeted mutagenesis to create strains of different phenotype for testing, PNEUMOPATH will be a systems biology approach with a checkerboard experimental design Panels of resistant/non-resistant carriage and disease pneumococcal isolates will be used to challenge in vivo and in vitro models, followed by integrated management and analysis of the data with a new semantic web bioinformatic infrastructure.

Keywords: pneumococcus,virulence,genomics,antibiotic resistance,epidemiology,systems biology,models of infection,genetics